Anixa Biosciences (ANIX)

• Market cap: $89.8M
• 1 day: 1.45%
• 5 days: 1.45%
• 1 month: -2.45%
• 3 months: -5.10%
• 6 months: -22.28%
• Year to date: 17.72%
• 1 year: -6.06%
• 5 years: 47.62%
• 10 years: -26.58%
• Sector: Healthcare
• Industry: Biotechnology

About: Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Employees: 6

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

224% more call options, than puts

Call options by funds: $201K | Put options by funds: $62K

38% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 8

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

0.71% more ownership

Funds ownership: 17.45% [Q3] → 18.16% (+0.71%) [Q4]

2% less funds holding

Funds holding: 58 [Q3] → 57 (-1) [Q4]

23% less capital invested

Capital invested by funds: $17.6M [Q3] → $13.6M (-$4.01M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7 151% upside
• Avg. target: $9 223% upside
• High target: $10 258% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 28% 1-year accuracy 107 / 376 met price target	258% upside $10	Buy Maintained	10 Apr 2025
HC Wainwright & Co. Yi Chen 33% 1-year accuracy 57 / 173 met price target	151% upside $7	Buy Reiterated	25 Mar 2025
Maxim Group Jason McCarthy 16% 1-year accuracy 5 / 32 met price target	258% upside $10	Buy Initiated	21 Mar 2025